Drug Profile
Risankizumab - AbbVie/Boehringer Ingelheim
Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZILatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer AbbVie; Boehringer Ingelheim
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Registered Erythrodermic psoriasis; Generalised pustular psoriasis
- Preregistration Ulcerative colitis
- Phase III Palmoplantar pustulosis
- Phase II Atopic dermatitis; Hidradenitis suppurativa
- No development reported Unspecified
- Discontinued Ankylosing spondylitis; Asthma
Most Recent Events
- 16 Jan 2024 Phase-III clinical trials in Psoriatic arthritis (In children, In adolescents, Treatment-experienced) in USA (SC) (NCT06100744) (EudraCT20235060263600)
- 29 Nov 2023 AbbVie completes an open-label extension phase III trial in plaque psoriasis in USA, Canada, Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Japan, South Korea, Mexico, Poland, Portugal, Spain, Sweden and Taiwan (NCT03047395) (EudraCT2016-003046-87)
- 20 Nov 2023 AbbVie initiates a phase I bioavailability trial (In volunteers) in US (IV, infusion) (NCT06054425),